RxDoctor Payments Data

Robert Malovany, MD

Internal Medicine · Englewood, NJNPI 1255355400

Payments from drug & device makers

$5,043in general payments, 2019–2025

Across 332 payments — averaging $15.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Boehringer Ingelheim$432
  • Amgen$300
  • Merck$275
  • Mallinckrodt Hospital Products Inc.$229
  • Sanofi$209
  • plus $2K from 45 others

What the payments were for

  • Food & beverage$5,043100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,043 in reported general payments places this provider in the 85th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$62,066
Medicare patients
221
Services billed
957

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter158$121,283
EliquisApixaban37$49,129
Breo ElliptaFluticasone/Vilanterol58$26,573
JardianceEmpagliflozin23$19,822
XareltoRivaroxaban12$14,528
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$9,144
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$9,033
SynjardyEmpagliflozin/Metformin Hcl14$8,589
Spiriva HandihalerTiotropium Bromide13$8,471
Incruse ElliptaUmeclidinium Bromide15$6,663
Rosuvastatin Calcium133$3,045
Icosapent Ethyl11$2,844
Albuterol Sulfate HfaAlbuterol Sulfate92$2,746
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$1,887
Atorvastatin Calcium156$1,604

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$1,276$163,663251 claims
PfizerEliquis$137$49,12937 claims
Boehringer IngelheimJardiance, Synjardy$432$28,41037 claims
Johnson & JohnsonXarelto$15$14,52812 claims
AstraZenecaBreztri Aerosphere$129$9,03314 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$1,087102 claims
AbbVieSynthroid$26$96711 claims
ANI Pharmaceuticals, Inc.Valsartan$32$47522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Englewood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →